BPC-157 vs GHK-Cu
How they differ
- FDA status, the same for both (Not FDA-approved). BPC-157: Not an FDA-approved drug.1 GHK-Cu: FDA compounding-list review for non-injectable routes.2
- HHS compounding policy of October 30, 2026. BPC-157 is one of the six peptides the policy lists; GHK-Cu is not.3
- Kinds of studies cited. BPC-157: limited human data. GHK-Cu: smaller controlled human trials. How these labels are assigned
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | BPC-157 | GHK-Cu |
|---|---|---|
| What it is | A 15-amino-acid peptide. FDA describes it as a fragment of a protein originally isolated from human gastric juice.1 | A copper-binding tripeptide, a chain of three amino acids (glycyl-histidyl-lysine) bound to copper, recorded by FDA as copper tripeptide-1.4,5 |
| FDA status | Not FDA-approved Not an FDA-approved drug1 Not FDA-approved. FDA staff recommended in May 2026 against adding it to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, BPC-157 is one of six listed peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action.1,3,6 | Not FDA-approved FDA compounding-list review for non-injectable routes2 No FDA approval is reported in the sources reviewed here. FDA lists GHK-Cu, except in injected forms, in category 1 (under evaluation) for the 503A compounding list, and lists injected GHK-Cu among withdrawn nominations with safety concerns.2,7 |
| HHS compounding policy, October 30, 2026 | In the policy: one of the six peptides it lists.3 | Not among the six peptides the policy lists.3 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHK-Cu is not among them.3,6 |
| FDA compounding safety-risk page | Listed. FDA’s compounding safety-risk page, last updated April 22, 2026, lists BPC-157 among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.7 | Listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists injected GHK-Cu among substances whose nominations were withdrawn, citing possible immune reactions and limited human safety data.7 |
| Kinds of studies cited |
| Smaller controlled human trials
|
| Records collected | 0 ClinicalTrials.gov records and 17 PubMed records collected | |
| Area of study | ||
| Latest dated events |
|
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1FDA briefing document for BPC-157-related bulk drug substances ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2503A bulk drug substances under evaluation · GHK-Cu except injectable routes · updated May 14, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked July 22, 2026
- 3HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 4Copper tripeptide-1 substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked July 29, 2026
- 5Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper (1994) · PMID 17147644 ↗
Wound Repair and Regeneration · Official source · Source checked November 14, 2026
- 6Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 7Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 8BPC 157 for Acute Hamstring Muscle Strain Repair · record history version 1 · last update posted 2026-02-27 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 9ClinicalTrials.gov record NCT07803250 · retained source version 2026-09-03:67a2d48128fcdff7f261f5c04e4a69cfe170396b0726d611a8db06ad7256abc0 ↗
ClinicalTrials.gov · Official source · Source checked September 9, 2026
- 10Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin (2006) · PMID 16847171 ↗
Archives of Facial Plastic Surgery · Official source · Source checked November 14, 2026
- 11July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026